Personalized Approach to the Management of GERD: GI Perspective

Knotts, Rita M.; Yadlapati, Rena

doi:10.1177/26345161211021763

Cited by 3 publications

(3 citation statements)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is limited research into behavioural therapies for patients with chronic laryngeal symptoms. Behavioural therapy targets the perseverant and nociceptive properties of laryngeal symptomatology 126 ; and thus, guidelines suggest hypnotherapy and cognitive behavioural therapy (CBT) may have a role in patients with chronic laryngeal symptoms. 12 Hypnotherapy has been primarily used in the treatment of irritable bowel syndrome; however, a growing body of literature has shown efficacy in upper GI disorders.…”

Section: Behavioural Therapymentioning

confidence: 99%

Review article: Diagnosis and management of laryngopharyngeal reflux

Krause,

Yadlapati

2024

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

SummaryBackgroundLaryngopharyngeal reflux has classically referred to gastroesophageal reflux leading to chronic laryngeal symptoms such as throat clearing, dysphonia, cough, globus sensation, sore throat or mucus in the throat. Current lack of clear diagnostic criteria significantly impairs practitioners' ability to identify and manage laryngopharyngeal reflux.AimsTo discuss current evidence‐based diagnostic and management strategies in patients with laryngopharyngeal reflux.MethodsWe selected studies primarily based on current guidelines for gastroesophageal reflux disease and laryngopharyngeal reflux, and through PubMed searches.ResultsWe assess the current diagnostic modalities that can be used to determine if laryngopharyngeal reflux is the cause of a patient's laryngeal symptoms, as well as review some of the common treatments that have been used for these patients. In addition, we note that the lack of a clear diagnostic gold‐standard, as well as specific diagnostic criteria, significantly limit clinicians' ability to determine adequate therapies for these patients. Finally, we identify areas of future research that are needed to better manage these patients.ConclusionsPatients with chronic laryngeal symptoms are complex due to the heterogenous nature of symptom pathology, inconsistent definitions and variable response to therapies. Further outcomes data are critically needed to help elucidate ideal diagnostic workup and therapeutic management for these challenging patients.

show abstract

Section: Behavioural Therapymentioning

confidence: 99%

Review article: Diagnosis and management of laryngopharyngeal reflux

Krause,

Yadlapati

2024

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Personalized treatment strategies tailored to individual patients are crucial, considering variations in symptom severity, treatment response, and complications. Acid suppression remains the mainstay of GERD treatment [ 40 , 41 ]. Factors such as diet, medications, obesity, smoking, and impaired mucosal barrier function also play a role [ 42 , 43 ].…”

Section: Gastroesophageal Reflux Disease (Gerd)mentioning

confidence: 99%

Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

Herdiana

2023

Polymers

View full text Add to dashboard Cite

Gastroesophageal Reflux Disease (GERD) is a chronic ailment that results from the backward flow of stomach acid into the esophagus, causing heartburn and acid regurgitation. This review explores nanotechnology as a novel treatment approach for GERD. Chitosan nanoparticles (CSNPs) offer several advantages, including biocompatibility, biodegradability, and targeted drug delivery capabilities. CSNPs have been extensively studied due to their ability to encapsulate and release medications in a controlled manner. Different nanoparticle (NP) delivery systems, including gels, microspheres, and coatings, have been developed to enhance drug retention, drug targeting, and controlled release in the esophagus. These nanoparticles can target specific molecular pathways associated with acid regulation, esophageal tissue protection, and inflammation modulation. However, the optimization of nanoparticle formulations faces challenges, including ensuring stability, scalability, and regulatory compliance. The future may see CSNPs combined with other treatments like proton pump inhibitors (PPIs) or mucosal protectants for a synergistic therapeutic approach. Thus, CSNPs provide exciting opportunities for novel GERD treatment strategies.

show abstract

“…In a little over 2.5 years, we have gone from a concept of becoming an integrated journal to developing a multidisciplinary collaborative editorial group, to completing 8 issues. 1,2 We have covered a wide variety of foregut topics including Barrett’s esophagus, 3 GERD, 4,5 esophageal motility, 6 obesity, 7 hiatal hernias, 8 esophageal cancer, 9 and achalasia. 10…”

mentioning

confidence: 99%